A potential therapeutic strategy for diabetes and its complications in the form of co-encapsulated antioxidant nanoparticles (NanoCAPs) of ellagic acid and coenzyme Q10: Preparation and evaluation in streptozotocin induced diabetic rats

D.V. Ratnam, G. Chandraiah, K.S.B. Viswanad, V. Bhardwaj, Poduri Ramarao, M.N.V.R. Kumar, Kiran Sonaje

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Diabetes is a metabolic disorder and is associated with serious complications caused by oxidative stress. The existing therapies only delay or reduce the severity of these complications but cannot completely prevent or reverse them. Antioxidant therapy is one promising alternative strategy to assuage these complications. However, the poor biopharmaceutical properties of many antioxidants limit their use as first line therapies. Here we propose a new therapeutic strategy to treat diabetes using biodegradable nano-co-encapsulated antioxidant particles (NanoCAPs) of ellagic acid (EA) and coenzyme Q(10) (CoQ(10)). The combination of EA and CoQ(10) showed beneficial effects in ameliorating lipid peroxidation, dyslipidemia and in preventing organ damage in streptozotocin induced diabetic rats. Significantly lower dose of EA and CoQ(10) in NanoCAPs showed equal and sometimes more prominent results in comparison to simple suspension suggesting improved efficacy Additionally, a statistically significant increase was observed in plasma insulin levels with nanoparticulate formulation of EA and CoQ(10) combination in comparison to simple suspension of EA, CoQ(10) alone or in combination as well as CoQ(10) nanoparticles. Collectively, this data indicates the potential use of NanoCAPs of EA and CoQ(10) in diabetes and reducing the associated complications.
LanguageEnglish
Pages33-43
Number of pages10
JournalJournal of Biomedical Nanotechnology
Volume4
Issue number1
DOIs
Publication statusPublished - Mar 2008

Fingerprint

coenzyme Q10
Ellagic acid
Ellagic Acid
Coenzymes
Ubiquinone
Diabetes Complications
Streptozocin
Medical problems
Antioxidants
Nanoparticles
Rats
Therapeutics
Suspensions
Oxidative stress
Insulin
Dyslipidemias
Lipids
Lipid Peroxidation

Keywords

  • antioxidants
  • coenzyme Q(10)
  • diabetes
  • ellagic acid
  • nanoparticles
  • oxidative damage

Cite this

@article{e79456c10cdd42748788fea4d09ca24b,
title = "A potential therapeutic strategy for diabetes and its complications in the form of co-encapsulated antioxidant nanoparticles (NanoCAPs) of ellagic acid and coenzyme Q10: Preparation and evaluation in streptozotocin induced diabetic rats",
abstract = "Diabetes is a metabolic disorder and is associated with serious complications caused by oxidative stress. The existing therapies only delay or reduce the severity of these complications but cannot completely prevent or reverse them. Antioxidant therapy is one promising alternative strategy to assuage these complications. However, the poor biopharmaceutical properties of many antioxidants limit their use as first line therapies. Here we propose a new therapeutic strategy to treat diabetes using biodegradable nano-co-encapsulated antioxidant particles (NanoCAPs) of ellagic acid (EA) and coenzyme Q(10) (CoQ(10)). The combination of EA and CoQ(10) showed beneficial effects in ameliorating lipid peroxidation, dyslipidemia and in preventing organ damage in streptozotocin induced diabetic rats. Significantly lower dose of EA and CoQ(10) in NanoCAPs showed equal and sometimes more prominent results in comparison to simple suspension suggesting improved efficacy Additionally, a statistically significant increase was observed in plasma insulin levels with nanoparticulate formulation of EA and CoQ(10) combination in comparison to simple suspension of EA, CoQ(10) alone or in combination as well as CoQ(10) nanoparticles. Collectively, this data indicates the potential use of NanoCAPs of EA and CoQ(10) in diabetes and reducing the associated complications.",
keywords = "antioxidants, coenzyme Q(10), diabetes, ellagic acid, nanoparticles, oxidative damage",
author = "D.V. Ratnam and G. Chandraiah and K.S.B. Viswanad and V. Bhardwaj and Poduri Ramarao and M.N.V.R. Kumar and Kiran Sonaje",
year = "2008",
month = "3",
doi = "10.1166/jbn.2008.011",
language = "English",
volume = "4",
pages = "33--43",
journal = "Journal of Biomedical Nanotechnology",
issn = "1550-7033",
number = "1",

}

A potential therapeutic strategy for diabetes and its complications in the form of co-encapsulated antioxidant nanoparticles (NanoCAPs) of ellagic acid and coenzyme Q10: Preparation and evaluation in streptozotocin induced diabetic rats. / Ratnam, D.V.; Chandraiah, G.; Viswanad, K.S.B.; Bhardwaj, V.; Ramarao, Poduri; Kumar, M.N.V.R.; Sonaje, Kiran.

In: Journal of Biomedical Nanotechnology, Vol. 4, No. 1, 03.2008, p. 33-43.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A potential therapeutic strategy for diabetes and its complications in the form of co-encapsulated antioxidant nanoparticles (NanoCAPs) of ellagic acid and coenzyme Q10: Preparation and evaluation in streptozotocin induced diabetic rats

AU - Ratnam, D.V.

AU - Chandraiah, G.

AU - Viswanad, K.S.B.

AU - Bhardwaj, V.

AU - Ramarao, Poduri

AU - Kumar, M.N.V.R.

AU - Sonaje, Kiran

PY - 2008/3

Y1 - 2008/3

N2 - Diabetes is a metabolic disorder and is associated with serious complications caused by oxidative stress. The existing therapies only delay or reduce the severity of these complications but cannot completely prevent or reverse them. Antioxidant therapy is one promising alternative strategy to assuage these complications. However, the poor biopharmaceutical properties of many antioxidants limit their use as first line therapies. Here we propose a new therapeutic strategy to treat diabetes using biodegradable nano-co-encapsulated antioxidant particles (NanoCAPs) of ellagic acid (EA) and coenzyme Q(10) (CoQ(10)). The combination of EA and CoQ(10) showed beneficial effects in ameliorating lipid peroxidation, dyslipidemia and in preventing organ damage in streptozotocin induced diabetic rats. Significantly lower dose of EA and CoQ(10) in NanoCAPs showed equal and sometimes more prominent results in comparison to simple suspension suggesting improved efficacy Additionally, a statistically significant increase was observed in plasma insulin levels with nanoparticulate formulation of EA and CoQ(10) combination in comparison to simple suspension of EA, CoQ(10) alone or in combination as well as CoQ(10) nanoparticles. Collectively, this data indicates the potential use of NanoCAPs of EA and CoQ(10) in diabetes and reducing the associated complications.

AB - Diabetes is a metabolic disorder and is associated with serious complications caused by oxidative stress. The existing therapies only delay or reduce the severity of these complications but cannot completely prevent or reverse them. Antioxidant therapy is one promising alternative strategy to assuage these complications. However, the poor biopharmaceutical properties of many antioxidants limit their use as first line therapies. Here we propose a new therapeutic strategy to treat diabetes using biodegradable nano-co-encapsulated antioxidant particles (NanoCAPs) of ellagic acid (EA) and coenzyme Q(10) (CoQ(10)). The combination of EA and CoQ(10) showed beneficial effects in ameliorating lipid peroxidation, dyslipidemia and in preventing organ damage in streptozotocin induced diabetic rats. Significantly lower dose of EA and CoQ(10) in NanoCAPs showed equal and sometimes more prominent results in comparison to simple suspension suggesting improved efficacy Additionally, a statistically significant increase was observed in plasma insulin levels with nanoparticulate formulation of EA and CoQ(10) combination in comparison to simple suspension of EA, CoQ(10) alone or in combination as well as CoQ(10) nanoparticles. Collectively, this data indicates the potential use of NanoCAPs of EA and CoQ(10) in diabetes and reducing the associated complications.

KW - antioxidants

KW - coenzyme Q(10)

KW - diabetes

KW - ellagic acid

KW - nanoparticles

KW - oxidative damage

UR - http://dx.doi.org/10.1166/jbn.2008.011

U2 - 10.1166/jbn.2008.011

DO - 10.1166/jbn.2008.011

M3 - Article

VL - 4

SP - 33

EP - 43

JO - Journal of Biomedical Nanotechnology

T2 - Journal of Biomedical Nanotechnology

JF - Journal of Biomedical Nanotechnology

SN - 1550-7033

IS - 1

ER -